IMRN IMRN
Company Profile ↓Company Overview
IMRN (IMRN) is a publicly traded company listed on with a market capitalization of $257.35M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 112.0% CAGR over the past five years.
Recent Developments
- Jun 2025 Revenue of $7.29M (+48.6% YoY); net profit $-5.22M.
- Trailing 12 Months Year-on-year growth — revenue +48.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 112.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 111.96% |
| 1 Year: | 48.63% |
Stock Price Performance
| 1 Year: | -32.93% |
| 6 Months: | +30.80% |
| 3 Months: | +39.42% |
| 1 Month: | -12.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Golden Cross9d ago
- RSI (14)47.44 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 112.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 53.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 765.19K | 1.80M | 4.90M | 7.29M |
| Cost of Revenue | 241.69K | 495.56K | 1.57M | 2.52M |
| Gross Profit | 523.50K | 1.31M | 3.34M | 4.77M |
| Operating Expenses | 3.64M | 4.72M | 8.55M | 10.12M |
| Operating Income | -3.12M | -3.41M | -5.22M | -5.36M |
| EBITDA | -2.81M | -3.73M | -6.88M | -5.16M |
| Interest Expense | 6.18K | 9.65K | 7.58K | 7.30K |
| Pretax Income | -2.85M | -3.79M | -6.94M | -5.22M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -2.85M | -3.79M | -6.94M | -5.22M |
| Diluted EPS | -0.50 | -0.66 | -1.22 | -0.91 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 24.86M | 21.99M | 15.55M | 10.13M |
| Current Assets | 23.67M | 20.41M | 14.73M | 10.02M |
| Cash & Equivalents | 22.11M | 17.16M | 11.66M | 2.83M |
| Inventory | 326.58K | 839.97K | 1.58M | 1.77M |
| Receivables | 208.34K | 19.03K | 591.20K | 791.39K |
| Total Liabilities | 1.68M | 2.37M | 2.84M | 2.06M |
| Current Liabilities | 1.50M | 2.22M | 2.70M | 1.97M |
| Long Term Debt | - | - | - | - |
| Total Debt | 209.79K | 189.09K | 132.94K | 71.86K |
| Total Equity | 23.18M | 19.62M | 12.71M | 8.07M |
| Shares Outstanding | 227.80M | 227.80M | 228.00M | 233.96M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - |
| Investing Cash Flow | 11.74K | -2.62M | 327.56K | -2.90M |
| Financing Cash Flow | -42.45K | -44.67K | 829 | 199.75K |
| Capital Expenditure | -10.05K | -7.74K | -195 | - |
| Free Cash Flow | -3.16M | -2.60M | -5.88M | -6.14M |
| Net Change in Cash | -3.18M | -5.26M | -5.55M | -8.84M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | 68.4% | 72.5% | 68.1% | 65.4% |
| Operating Margin % | -407.4% | -188.8% | -106.4% | -73.5% |
| Net Margin % | -373.0% | -209.8% | -141.5% | -71.6% |
| ROE % | -12.3% | -19.3% | -54.6% | -64.6% |
| ROCE % | -13.3% | -17.2% | -40.6% | -65.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMRN
Immuron's Travelan Sales Grow for Four Straight Quarters - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPZDlzUF9pa3kxLXkwMmFsVE9jSVgzcTVPN0lQcXc5UmNtbkR3MExMX0NQRDZfLTAxdmtSaU14VVdHenZLTXkxVUlpd2pIUVRhWjVzM3o4SzhOZ3hFbkNObUNkbDh4RTEtMDdPSDZRdUYwOXpxUG1SRW9MVVhrOGR3NFV6U2J2cV9YS2FlYz…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE80QlhoNWFIdE91Qm1hSXFybE5UUXdEYzNHOXVNSVBKc2RiTFBZOWFfdmlMLTV0YkZuWDl4SmEzT3E3Vzh1RWo1X2RUZEhqR2c2?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Immuron’s Travelan uses oral antibodies to reduce diarrhea risk - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPdU5sMFZwaGRLc0RLSjJad0VBSUc1ZmxhN3NCcjktM0hDczk1SkNRSGlrU0ZjbmUtWm9QTkg4Zy1BSFNsQVoyU0drQkFCYVppZEhUSk1SSFF5Nm02LVNZUXVUWUF2dDAwd1JMaDdqejhsSXJnaFRsS01DNzN4eGl4SldiMkZGVFpiZ25TWW…
IMRN|Immuron Ltd|Price:1.080|Chg%:+0.020 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE91RTVwSUczcGl2Q1lZZWVaaWc3VEp0b294elpyNm4yZHFoN2FXU2dCM1pYNjBDMXh6SjhHczJDLXhaRTBFdTFVTmJmM2gxVF8xdWZGSE5PSnJUbHdMaHk3VE4zVG01eTgwMXZ0UzZB?oc=5" target="_blank">IMRN|Immuron Ltd|Pr…
Immuron (IMRN) Slips 1.68% as Shares Test Near Support Levels - Jelly Roll Trade - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPVEVRT3U5N1ItTWlyaHpVc3VXWXRRWTBVU0thaEtPLWhXUVpsRWc0ajdFb0l3X0Y5U0hCZ0NIU080OWV2Y1dicjgzbmFrekx0TlFmR3Fnclo2emdMNnpWbmhaWlNoVmdMeHc0bXh0cmhFNUZGcFMwd0pQcHNHZHVSYm9FQkc1ZTh1WjN4aX…
Immuron (NASDAQ: IMRN) outlines FY26 growth, cash runway and CDI IND plans - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOODJiUHZmaU1qd08zUkx0TzNqYldkVzdMQmNRLW5uSy1yTFptMVVhWmg4WjF3VjZhOGZyM2VIQlI4MGRDMnJ3NXNheWN4TWtJa2dKVGFKZUZMdlJIOUh6dE9LYVdBUGVLNFh2QzJCOGtvWGxUclotZXRsd1JHbGNWYWItbUhhcDJwRXRSZk…
IMRN — Frequently Asked Questions
What is the current share price of IMRN?
As of 2026-08-05 17:25 PDT, IMRN trades at $1.10 on NASDAQ/NYSE. Its 52-week range is $0.70 to $2.35.
What is the market capitalisation of IMRN?
IMRN has a market capitalisation of $257.35M on NASDAQ/NYSE.
What is the P/E ratio of IMRN?
IMRN trades at a trailing price-to-earnings (P/E) ratio of -1.21. Its price-to-book (P/B) ratio is 31.88.
What is the return on equity (ROE) of IMRN?
IMRN has a return on equity (ROE) of -64.64%. Its return on capital employed (ROCE) is -65.62%.
Is IMRN a good stock to buy?
This page provides a data-driven analysis of IMRN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.